Royal Bank of Canada set a $19.00 price target on Allscripts Healthcare Solutions (NASDAQ:MDRX) in a report published on Thursday. The brokerage currently has a buy rating on the software maker’s stock.

Several other equities research analysts have also commented on MDRX. Cantor Fitzgerald reiterated a buy rating and set a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Wednesday, September 27th. Maxim Group reiterated a buy rating and set a $20.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Tuesday, January 9th. Dougherty & Co reiterated a buy rating and set a $16.00 price objective (up from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 3rd. Citigroup assumed coverage on Allscripts Healthcare Solutions in a research note on Thursday, January 4th. They set a buy rating for the company. Finally, BidaskClub upgraded Allscripts Healthcare Solutions from a hold rating to a buy rating in a research note on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. Allscripts Healthcare Solutions presently has a consensus rating of Buy and an average price target of $15.53.

Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up $0.09 during midday trading on Thursday, reaching $16.03. The company had a trading volume of 1,439,500 shares, compared to its average volume of 1,970,689. The firm has a market cap of $2,900.00, a PE ratio of -13.82, a price-to-earnings-growth ratio of 2.27 and a beta of 1.32. Allscripts Healthcare Solutions has a 12 month low of $11.01 and a 12 month high of $16.13. The company has a quick ratio of 0.98, a current ratio of 0.98 and a debt-to-equity ratio of 1.20.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings results on Thursday, November 2nd. The software maker reported $0.12 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.12. Allscripts Healthcare Solutions had a positive return on equity of 6.53% and a negative net margin of 12.23%. equities analysts anticipate that Allscripts Healthcare Solutions will post 0.46 EPS for the current fiscal year.

In other news, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $14.26, for a total value of $213,900.00. Following the completion of the sale, the president now directly owns 1,351,773 shares in the company, valued at $19,276,282.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP James Hewitt sold 36,796 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $14.11, for a total value of $519,191.56. Following the completion of the sale, the senior vice president now owns 181,766 shares of the company’s stock, valued at $2,564,718.26. The disclosure for this sale can be found here. Insiders sold 56,796 shares of company stock valued at $804,842 over the last 90 days. Company insiders own 0.91% of the company’s stock.

Several hedge funds have recently bought and sold shares of MDRX. Fisher Asset Management LLC purchased a new stake in shares of Allscripts Healthcare Solutions in the third quarter valued at approximately $33,351,000. Dimensional Fund Advisors LP grew its position in shares of Allscripts Healthcare Solutions by 26.9% in the second quarter. Dimensional Fund Advisors LP now owns 9,171,285 shares of the software maker’s stock valued at $117,026,000 after purchasing an additional 1,943,496 shares in the last quarter. Systematic Financial Management LP grew its position in shares of Allscripts Healthcare Solutions by 1,215.3% in the third quarter. Systematic Financial Management LP now owns 1,853,300 shares of the software maker’s stock valued at $26,372,000 after purchasing an additional 1,712,395 shares in the last quarter. State Street Corp grew its position in shares of Allscripts Healthcare Solutions by 28.6% in the second quarter. State Street Corp now owns 5,975,551 shares of the software maker’s stock valued at $76,251,000 after purchasing an additional 1,330,721 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Allscripts Healthcare Solutions by 70.8% in the second quarter. Northern Trust Corp now owns 2,930,365 shares of the software maker’s stock valued at $37,391,000 after purchasing an additional 1,215,020 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/royal-bank-of-canada-analysts-give-allscripts-healthcare-solutions-mdrx-a-19-00-price-target/1808547.html.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.